ad image

mRNA Vaccines

1 / 1
Revolutionizing xRNA Production: The Economic Case for Continuous Manufacturing
xRNA

Revolutionizing xRNA Production: The Economic Case for Continuous Manufacturing

Aaron B. Cowley, Ph.D.

ReciBioPharm

PAO-02-25-CL-11Feb 13, 2025
Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with Enzymatically Generated z- dbDNA
RNA

Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with Enzymatically Generated z- dbDNA

Lisa Caproni

Touchlight

PAO-01-25-CL-08Feb 10, 2025
BioVaxys Technology Corp
DPX

BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a Market Projected to Grow to USD$48,000,000,000 by 2030

BioVaxys Technology Corp

PR-01-25-NI-20Jan 17, 2025
1 / 1